The Bel-2 proto-oncogene was discovered at the t(14;18) breakpoint found in most follicular B-cell lymphomas and some diffuse large-cell lymphomas. Bcl-2 is unique among proto-oncogenes, being localized to mitochondria and extending cell survival by blocking programmed cell death. We examined Bcl-2 protein expression in 82 hematologic malignancies and reactive lymphoid processes. All lymphomas with Bcl-2 rearrangement demonstrated high levels of Bcl-2 protein. However, most follicular and diffuse lymphomas without Bcl-2 rearrangement also displayed intense Bcl-2 staining. In these cases, mechanisms other than classic translocation may be deregulating Bcl-2. The pattern of Bcl-2 staining in follicular lymphoma is the inverse of the pattern in reactive hyperplasia, confirming a role for Bcl-2 immunolocal-ALIGNANCIES possess distinct interchromosomal
threefold to fourfold excess of small, resting IgMDgD B cells because of extended survi~al.'~"~ Moreover, the transgenic mice establish that prolonged cell life is tumorigenic as they progress to high grade malignant lymphomas. '6 Immunohistochemical examination of normal lymphoid tissues with monoclonal antibodies (MoAbs) specific for human Bcl-2 protein'' showed a tight topographic distribution of B~l-2."~"~'~ Within postimmune germinal centers, Bcl-2 protein was most abundant in the long-lived recirculating B cells of the follicular mantle."^'* Provocatively, Bcl-2 was absent from the centroblasts and centrocytes destined to die within the dark zone and basal light zone. In parallel, surviving T cells within the medulla of the thymus demonstrate substantial Bcl-2 while those in the cortex are negati~e.".'~ The discreet topographic restriction of Bcl-2 in normal lymphoid organs prompted this immunohistochemical evaluation of Bcl-2 in 82 cases of hematologic malignancy. We wished to determine if lymphoid neoplasms would conserve this patterned distribution of Bcl-2 reflecting their sites of origin. Alternatively, significant Bcl-2 protein might only be present in the tumors with chromosomal rearrangement that deregulated the Bcl-2 gene. 19 We also sought to contrast the architectural distribution of Bcl-2 in reactive lymphoid processes versus malignancy to assess the diagnostic value of Bcl-2 immunohistochemistry. Finally, an assessment of Bcl-2 protein would identify the spectrum of hematologic neoplasms in which a Bcl-2-mediated survival advantage participated.
MATERIALS AND METHODS

Immunohistochemistry.
Lymphoid tissue was obtained from material submitted to the surgical pathology division of the Department of Pathology, Washington University School of Medicine. The tissue was embedded in OCT compound (Miles Laboratories, Elkhart, IN), snap-frozen in liquid cooled isopentane, and stored at -70°C. The histologic diagnosis was based on conventional hematoxylin-stained, formalin-fixed, paraffin-embedded sections.
Subclassification of the malignant lymphomas was according to the Working Formulation for clinical usage.2o Immunophenotyping was performed on either cell suspensions prepared at the time of biopsy by flow cytometric analysis or by frozen section immunohistochemistry?' Frozen sections (6 )L) were cut, fixed briefly in acetone, and held at -20°C before staining by the avidin-biotin complex, immunoperoxidase technique. Frozen sections were required because the epitope recognized by the MoAb was destroyed by formalin fixation. Either the hamster MoAb 6C8, monospecific for the human Bcl-2 protein, or the control hamster antirecombinant interleukin-2 (rIL-2) MoAb, specific for murine IL-2, was used at a concentration of 5 to 10 &mL. The generation of 6C8 and its specificity is described elsewhere." A biotinylated goat-antihamster IgG (1:40 dilution) and an avidin-biotin complex (ABC) reagent (Vector Laboratories, Burlingame, CA) was used for detection. Peroxidase activity was detected by incubation with a solution of diaminobenzidene with histomark orange (Kirkegaard and Perry Labs, Gaithersburg, MD) and counterstained with methyl green and alcian blue.
A quantitative estimate of cytoplasmic staining intensity (0 to 5+) was based on a comparison of the staining intensity of malignant cells with that of normal lymphoid organs. 
(SDS).
Probes.
RESULTS
Bcl-2 protein was evaluated in 82 hematopoietic malignancies or reactive lymphoid processes with MoAb 6C8, monospecific for the human 25-Kd Bcl-2 protein. Normal or reactive lymphoid follicles and inflammatory infiltrates of the skin or orbit were examined (Table 1) to provide a basis for comparison with malignant lymphomas and leukemias. We assessed the intensity and distribution of Bcl-2 expression in five reactive lymph nodes. Consistently, Bcl-2 was strongly positive (3 to 4+) in the mantle zone compartment, predominantly absent from follicular centers, and of inter- (Table 2 ) including small cleaved, mixed large and small cleaved, and predominantly large cell lymphomas. Staining often demonstrated only a nodular distribution or demonstrated both areas with a nodular pattern and areas with a uniform staining intensity. The areas of uniform Bcl-2 expression correspond to areas of diffuse involvement. The malignant follicles were intensely positive (3 to 4+) and surrounded by a small rim of weakly positive cells (2+) (Fig 1B) . This pattern of Bcl-2 staining was the inverse of that demonstrated by normal lymphoid follicles. In only two follicular lymphomas, a small cleaved cell lymphoma and a mixed large and small cell lymphoma, was Bcl-2 expression weak. In these cases, expression was 1+ or 1 to 2+ when compared with normal mantle zone lymphocytes. In both cases, the weak pattern of Bcl-2 expression was uniform in distribution and contrasted sharply with the nodular pattern of Bcl-2 in the other cases.
Frozen tissue for DNA analysis was available in 13 cases and seven of those demonstrated a Bcl-2 rearrangement by Southern blot analysis. The t(14;18) involved the MBR in four of the cases or the 5' untranslated region of the Bcl-2 gene in three cases. No rearrangements in the 3' mcr were present. Although the cases evaluated were chosen randomly, the incidence of Bcl-2 rearrangement in the follicular small cleaved cell category is lower than expected. The intense 3 to 44-Bcl-2 expression was not restricted to the subset of follicular lymphomas with documented Bcl-2 rearrangements.
In addition, four cases of diffuse small cleaved cell lymphoma showed strong (3 to 4+) Bcl-2 protein (Table 3) . DNA analysis performed on two of these cases (cases 3A and 3B) showed no evidence of a t(14;18). In three of these four cases the distribution of Bcl-2 expression demonstrated a nodular staining pattern either with or without areas showing a uniform pattern of Bcl-2. The cases with both nodular and uniform areas suggest that these three lymphomas had both a follicular and diffuse growth pattern. The follicular nature of the process had been missed on routine hematoxylin and eosin staining.
Evaluation of nine cases of small lymphocytic malignancy included three cases of small lymphocytic (well-differentiated) malignant lymphoma, three cases of intermediate lymphoma (mantle zone type), and three cases of chronic lymphocytic leukemia (CLL). The staining intensity for Bcl-2 was intermediate (2+) and was therefore less intense than the mantle zone in a normal reactive lymph node ( Table 3) . The mantle zone lymphomas demonstrated residual Bcl-2-negative follicular centers that were compressed by the expanding population of mantle zone lymphocytes (Fig 2A) . The lymphocytes from either the bone marrow or peripheral blood of three CLL cases showed For personal use only. on October 30, 2017. by guest www.bloodjournal.org From Detection of Bcl-2 rearrangement in the MBR. mcr, and 5' region of the Bcl-2 gene was performed by Southern blot hybridization using the restriction enzymes and probes described in Materials and Methods. Of note, the incidence of MBR rearrangement in the 16 cases is lower than that observed in large series.
uniform 2+ expression of Bcl-2 by all the lymphoid cells. The intensity of staining was similar to that of the small lymphocytic lymphomas. The four cases evaluated by DNA analysis showed no rearrangement of Bcl-2.
Intense (3 to 4+) uniform Bcl-2 expression was demonstrated by 10 of 14 diffuse large cell lymphomas ( Table 4) (Fig 2B) , and three of four immunoblastic lymphomas of B-cell origin. In three of the remaining cases, Bcl-2 was intermediate (2+) in intensity, and in only two cases was Bcl-2 weakly (1+) present. In four of the 14 cases tested, a Bcl-2 rearrangement was identified, which involved the MBR in three cases and the 5' region in one case. Strong Bcl-2 expression was noted in the four cases with a t(14;18) rearrangement. However, high level Bcl-2 was not restricted to the 28% of large cell lymphomas that demonstrated t(14;18) rearrangements.
Considerable variability in staining was observed in plasma cell dyscrasia (Table 5 ). In two plasmacytomas, the malignant plasma cells expressed Bcl-2 either weakly (1 to 2+) or very strongly (5+) (Fig 2C) . This low level of Bcl-2 expression (1 to 2+) is similar to the expression of the nonmalignant plasma cells identified in bone marrow aspirates. In the two cases of multiple myeloma evaluated in bone marrow aspirate smears, Bcl-2 was weak (1 to 2+). Morphologic evaluation of the three cases with weak Bcl-2 expression showed minimal atypia. In contrast, the plasma- cytoma with increased Bcl-2 was composed of large anaplastic plasma cells. In contrast to the B-cell lymphomas, most lymphomas of T-cell origin expressed lower levels of Bcl-2 protein ( Table  6 ). Immunohistochemical staining of three lymphoblastic lymphomas (CDl+, CD3+, CD4', and CDV) with antiBcl-2 exhibited 0 or 1+ reactivity (Fig 2D) . Diffuse large cell peripheral T-cell lymphomas, which expressed a mature phenotype (CD1-, CD3', CD4+, or CD8+), exhibited intermediate staining (1 to 2+) (Fig 2E) . The intensity of Bcl-2 throughout the mature, large T-cell lymphomas was variable and usually not as intense as in most B-cell lymphomas of a similar morphologic subtype. There was overlap in staining intensity between the diffuse large-cell lymphomas of B-cell origin that were weak to intermediate for Bcl-2 staining and the most intense large-cell lymphomas of T-cell origin. In addition, one case of mycosis fungoides and one case of lymphomatoid papulosis showed staining similar to peripheral T cells (2+).
Immunohistochemistry on lymph nodes from nine cases of Hodgkin's disease showed a pleomorphic population of cells expressing different degrees of Bcl-2 (Table 7) (Fig  2F) . The small lymphocytic infiltrate surrounding the ReedSternberg (R-S) cells, which immunophenotypically were primarily CD2, CD3, CD5, and CD4 or CD8 positive mature T cells, expressed intermediate levels (2+) of Bcl-2. The expression was similar to the expression by the interfol- Table 6 .
T-cell Lymphomas
Case No. Chronic myelogenous leukemia presenting in either soft tissue or spleen (two cases) showed intense Bcl-2 staining (3 to 4+) (Fig 2G) . The strong expression of Bcl-2 by immature myeloid precursors, including blasts, promyelocytes, and myelocytes, is comparable with the distribution of Bcl-2 in the myeloid series in normal marrow."
Bcl-2 Distribution
DISCUSSION
The t( 14;18) results in deregulated expression of the Bcl-2-Ig fusion gene in the majority of follicular, small cleaved cell lymphomas and some diffuse large-cell lymphomas. Thus, a clear rationale existed for examining Bcl-2 protein in lymphomas with a t(14;18). However, its potential importance in hematopoietic neoplasms lacking evidence of a translocation also needed assessment. The recent immunolocalization of Bcl-2 protein demonstrated a distinct topographic distribution in normal lymphoid tissue. Bcl-2 protein is restricted to the regions of surviving lymphocyte populations in both germinal centers and thy-US.",^* In that context, it was important to determine the spectrum of hematopoietic neoplasms in which Bcl-2 protein was present and compare that with normal development. For personal use only. on October 30, 2017. by guest www.bloodjournal.org From Follicular lymphomas as well as diffuse small cleaved cell lymphomas both with and without evidence of Bcl-2 rearrangement express high levels of Bcl-2, with only rare exceptions. The nodular distribution of Bcl-2 corresponds to the nodular growth pattern of follicular lymphoma. All follicular lymphomas with a Bcl-2 rearrangement in the MBR, mcr, or 5' region displayed high levels of Bcl-2. However, many cases with no identifiable rearrangement in the classic sites also expressed high levels of Bcl-2 protein.
The lack of detectable rearrangements suggests that mechanisms other than translocation in these sites may deregulate Bcl-2 expression. Possible deregulatory events include rearrangements in other unidentified breakpoint regions or somatic mutation in the 5' region of the bcl-2 gene.9 Occasional small cleaved cell, both diffuse and follicular, lymphomas had only low levels of Bcl-2. Because these cases were otherwise indistinguishable, the possibility exists that this subset of malignant B cells may possess other genes that confer a survival advantage.
The strong nodular pattern of Bcl-2 staining in follicular lymphomas is the inverse topography of the normal reactive germinal center.I7 That includes follicular lymphomas without detectable Bcl-2 rearrangement and suggests that they represent deregulation of Bcl-2 rather than an expansion of a normal counterpart with high Bcl-2 expression. The distinct contrast in the pattern of Bcl-2 expression between reactive follicular hyperplasia and malignant follicular lymphoma concurs with the findings of Pezzella et a1 and Ngan et al.'7319 Immunolocalization of Bcl-2 expression is a useful diagnostic adjunct in discriminating malignant lymphoma from reactive follicular hyperplasia.
Small lymphocytic malignancies, including diffuse small lymphocytic (well-differentiated) and intermediate cell (mantle zone lymphoma), expressed modest amounts (2+) of uniformly distributed Bcl-2 protein. Mantle zone lymphoma showed a similar topographic distribution of Bcl-2 to normal lymphoid follicles in which follicular centers are negative. In contrast to the mantle zone in a reactive hyperplasia, mantle zone lymphomas compress and obliterate the normal follicular center and expand diffusely as a uniform population of Bcl-2-positive cells. Small lymphocytic lymphomas (well-differentiated) demonstrate a similar intensity and uniform distribution of Bcl-2 as mantle zone lymphomas; however, residual Bcl-2-negative follicular centers are not seen. The similarity in Bcl-2 staining correlates with the similarities in immunophenotype and the indolent clinical course of these disease^.^'^^ CLL expresses Bcl-2 in a uniform intensity comparable with that of well-differentiated lymphocytic lymphomas. CLL is a long-lived recirculating B-cell neoplasm with a low proliferative index. A low percentage of CLLs have been shown to have rearrangements in the 5' regulatory region of B~l-2.~'
Most diffuse large-cell lymphomas of B-cell immunophenotype demonstrate strong Bcl-2 staining. Bcl-2 expression in the large-cell lymphoma category is often independent of rearrangement in the MBR, mcr, or 5' region of Bcl-2. This observation suggests several alternative explanations. Largecell lymphomas might represent transformation of a B-cell subset with inherently high Bcl-2 production. Alternatively, mechanisms of Bcl-2 deregulation beyond classic translocation may prove more important than in follicular small-cell lymphomas.
Bcl-2 expression in plasma cell dyscrasias is variable and may depend on cell morphology. Two cases of multiple myeloma and a plasmacytoma showed only low levels of Bcl-2 similar to normal plasma cells. A plasmacytoma composed of large anaplastic plasma cells showed the most intense Bcl-2 expression of all neoplasms evaluated.
Bcl-2 protein in T-cell lymphomas appears to reflect their corresponding stage of T-cell development. Lymphoblastic lymphomas with an immature T-cell phenotype, which corresponds to cells in the thymic cortex (Tdt, CD1, CD2, CD3, CD4, and CD8 positive), fail to express Bcl-2. Most Tdt', CD1' cells in the normal thymic cortex lack Bcl-2 protein; Bcl-2 is strongly expressed by the more mature T cells present in the thymic m e d~l l a . '~, '~ In contrast to the findings in B-cell lymphomas, diffuse large-cell and smallcell lymphomas of mature T-cell phenotype demonstrate only weak to intermediate Bcl-2 staining (1 to 2+). This level of Bcl-2 is consistent with that normally found in the interfollicular T-cell compartment and recirculating T cells. In addition, translocations involving Bcl-2 do not occur frequently in T-cell lymphoma.
A potential role for the t(14;18) in the pathogenesis of Hodgkin's disease was recently proposed by StetlerStevenson et al.M In their study of 53 lymph nodes of Hodgkin's disease, 17 cases displayed evidence of a Bcl-2 translocation by a polymerase chain reaction (PCR) assay. However, the source of such amplified products was uncertain in tissue from Hodgkin's disease, composed of a polymorphous mixture of R-S cells, small lymphocytes, plasma cells, and histiocytes. Within the nodular sclerosing type of Hodgkin's disease we found no substantial staining for Bcl-2 (0 to 1+) within the R-S cells. In contrast, the small lymphoid population composed primarily of reactive T cells, occasional B cells, and plasma cells, expressed intermediate levels of Bcl-2. Thus, this study provides no support for the deregulation of Bcl-2 in the genesis of R-S cells.
The strong Bcl-2 expression in two cases of chronic myelogenous leukemia is compatible with the recent findings that demonstrate Bcl-2 protein in normal hematopoietic precursors.18 Bcl-2 is most strongly expressed by the early myeloid progenitors, including blasts, promyelocytes, and myelocytes. Bcl-2 protein decreases with maturation to a metamyelocyte or band stage and is nearly absent in neutrophils. This finding is consistent with a role for Bcl-2 in maintaining stem cells and proliferating hematopoietic progenitor cells.
Bcl-2 interferes with programmed cell death independent of promoting cell division."^" Bcl-2 extends the survival of selected hematopoietic cell types following cytokine deprivation while others are unaffected." Transgenic mice bearing a Bcl-2-Ig minigene that recreates the t( 1438) establish a causative role for this translocation in tumorigenesis.'"16 Overproduction of Bcl-2 extends the survival of resting B cells that over time acquire secondary genetic
For personal use only. on October 30, 2017. by guest www.bloodjournal.org From changes and progress to diffuse large-cell lymphomas. This study documents high levels of Bcl-2 protein in all neoplasms with evidence of a Bcl-2 rearrangement. However, high levels of Bcl-2 are not limited to such cases, emphasizing that translocation may not be the sole mechanism for deregulating Bcl-2. These observations identify a broader spectrum of hematopoietic neoplasms in which a Bcl-2-mediated survival advantage may operate.
